Prices Drove Spending Growth: Trends In Employer-Sponsored Insurance Costs, 2014-2018
(2/13, Niall Brennan, Jean Fuglesten Biniek and John Hargraves, Health Affairs Blog) comments “...Drawing on 2.5 billion medical and pharmacy claims from four of the largest national health insurers, the latest annual report from the Health Care Cost Institute shows that average health care spending climbed to an all-time high in 2018 of $5,892 per person for individuals with health insurance coverage through an employer. That amounts to an average annual growth rate of 4.3 percent between 2014 and 2018...The increase in health care spending is particularly concerning because nearly three-quarters of the increase in inflation-adjusted spending was due to rising prices.” Full
Supporting the Safety Net through Research Training and Engagement
(2/14, Adney Rakotoniaina, The PCORI Blog) comments “...Health center patients often have chronic health issues that are compounded by difficulties resulting from social factors. FQHCs, and the state Primary Care Associations which support them, face challenges in meeting the complex health needs of their patients. Given this, Eugene Washington PCORI Engagement Awards teams across the country are helping health center patients and clinicians drive research important to them to better meet these needs.” Full
Morningstar's Report on Socially Conscious Investment Strategies
(2/14, David Whitrap, ICER Blog) comments “...Increasingly, the more forward-thinking biopharma companies are rolling up their sleeves to engage fully in ICER's assessments. They're aware that a favorable ICER report provides 1) a reputational boost for their company among legislators and the general public, 2) improved leverage when negotiating with payers, and 3) a progressive pitch to investors who are looking to put their money behind socially responsible companies.” Full
Scotland Recommends Interim Funding For Regeneron/Sanofi's Libtayo
(2/14, Francesca Bruce, Pink Sheet) reports “...Scotland's health technology assessment body, the Scottish Medicines Consortium, has accepted Regeneron Pharmaceuticals Inc. / Sanofi's conditionally approved skin cancer treatment, Libtayo (cemiplimab), for interim funding on the Scottish National Health Service. Other treatments that recently got the thumbs up from the SMC include Pierre Fabre Group's Braftovi (encorafenib), also for skin cancer, and Takeda Pharmaceutical Co. Ltd.'s Revestive (teduglutide) for short bowel syndrome.” Paid Subscription Required
Physician and Patient Adjustment to Reference Pricing for Drugs
James C. Robinson, PhD, et al.
February 5, 2020, JAMA Network Open
JAMA Network Open
Establishment of a Patient-Centered Outcomes Research Network for Individuals with TBI and Neuropsychiatric Symptoms
Rao VA, et al.
February 12, 2020, Brain Injury
CAR-T Therapy and Historical Trends in Effectiveness and Cost–Effectiveness of Oncology Treatments
James R Baumgardner, et al.
February 14, 2020, Journal of Comparative Effectiveness Research Journal of Comparative Effectiveness Research
Adding Pertuzumab to Adjuvant Therapy for High-Risk HER2-Positive Early Breast Cancer in APHINITY: A GRADE Analysis
Alberto Zambelli, et al.
February 14, 2020, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
2018 Health Care Cost and Utilization Report
Health Care Cost Institute
PCORI Board of Governors Meeting
March 2, 2020
2:30 - 7:30PM EST